^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anyouping (finotonlimab)

    i
    Other names: SCT-I10A, SCT-I10, SCT I10A, SCTI10A
    Associations

    News

    Trials
    Company:
    Sinocelltech
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5d
    LONG'E: Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC (clinicaltrials.gov)
    P1, N=10, Recruiting, Beijing Tongren Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Anyouping (finotonlimab) • Kangyueda (stapokibart)
    6d
    Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs. (PubMed, BMC Gastroenterol)
    PIB demonstrates superior survival and tumor response benefits over sorafenib as initial treatment in patients with advanced HCC, with an acceptable and manageable safety profile.
    P3 data • Retrospective data • Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Avastin (bevacizumab) • sorafenib • Anyouping (finotonlimab)
    17d
    A prospective, single-arm, clinical study of finolizumab combined with TP induction regimen in the treatment of resectable locally advanced hypopharyngeal squamous cell carcinoma (ChiCTR2600121672)
    P1, N=30, Recruiting, The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University
    New P1 trial
    |
    Anyouping (finotonlimab)
    3ms
    A prospective, multicenter, randomized, controlled, open-label trial to evaluate the efficacy and safety of Finotonlimab in locally advanced head and neck squamous cell carcinoma (ChiCTR2600117055)
    P4, N=292, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P4 trial
    |
    Anyouping (finotonlimab)
    3ms
    A Prospective, Single-Arm, Phase II Clinical Study of Finotonlimab Combined with Carboplatin and Nab-Paclitaxel in the Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (ChiCTR2500112241)
    P2, N=35, Not yet recruiting, SUN YAT-SEN MEMORIAL HOSPITAL; SUN YAT-SEN MEMORIAL HOSPITAL
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • Anyouping (finotonlimab)
    5ms
    Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=116, Recruiting, Eye & ENT Hospital of Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • albumin-bound paclitaxel • Anyouping (finotonlimab)
    6ms
    Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=116, Not yet recruiting, Eye & ENT Hospital of Fudan University
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Anyouping (finotonlimab)
    6ms
    Induction chemotherapy combined with Finotonlimab ± high and low-dose radiotherapy in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: a Multi-center, Open-label,Randomized Controlled Phase II Clinical Trial (ChiCTR2500109989)
    P2, N=84, Not yet recruiting, Jiangxi cancer hospital; Jiangxi cancer hospital
    New P2 trial
    |
    cisplatin • paclitaxel • Anyouping (finotonlimab)
    7ms
    Cost-effectiveness analysis of first-line treatments for recurrent or metastatic head and neck cancer in China: an economic evaluation based on network meta-analysis. (PubMed, Front Pharmacol)
    From the perspective of the Chinese population, finotonlimab-chemotherapy is the most cost-effective first-line treatment for R/M HNSCC, followed by cetuximab-chemotherapy. Pembrolizumab, whether as monotherapy or in combination, does not offer economic benefits.
    Retrospective data • Journal • HEOR • Cost-effectiveness
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • Anyouping (finotonlimab)
    8ms
    An anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) and chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib study. (PubMed, Cancer Lett)
    Immunotherapy has demonstrated limited efficacy against microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Oxaliplatin may induce greater immune activation, with GZMA and CXCL13 serving as potential prognostic biomarkers. Thus, combining immunotherapy, EGFR inhibitors, and XELOX represents an optimal therapeutic strategy for mCRC.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • GZMA (Granzyme A)
    |
    BRAF wild-type
    |
    capecitabine • oxaliplatin • SCT200 • Anyouping (finotonlimab)
    9ms
    Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/ Metastatic HNSCC ( LONG'E ) (ChiCTR2500105767)
    P1, N=10, Not yet recruiting, Bejing Tongren Hospital, Capital Medical Uniersity; Bejing Tongren Hospital, Capital Medical Uniersity
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Anyouping (finotonlimab) • Kangyueda (stapokibart)
    11ms
    LONG'E: Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Beijing Tongren Hospital
    New P1 trial
    |
    Anyouping (finotonlimab) • Kangyueda (stapokibart)